本文選題：熱毒寧注射液　切入點(diǎn)：頭孢哌酮舒巴坦鈉　出處：《中華中醫(yī)藥學(xué)刊》2017年03期

【摘要】：目的:探討熱毒寧聯(lián)合頭孢哌酮舒巴坦鈉對(duì)多重耐藥菌呼吸道感染患兒臨床療效及安全性。方法:選擇65例多重耐藥菌呼吸道感染患兒進(jìn)行隨機(jī)分組對(duì)照研究,對(duì)照組32例患兒予頭孢哌酮舒巴坦靜點(diǎn)治療,治療組33例患兒在此基礎(chǔ)上予熱毒寧注射液輔助治療,3 d為1個(gè)療程,兩組患兒均治療1個(gè)療程。通過(guò)比較治療前后兩組患兒臨床癥狀變化以及治療后的總有效率和TESS評(píng)分來(lái)探究熱毒寧聯(lián)合頭孢哌酮舒巴坦鈉對(duì)多重耐藥菌呼吸道感染患兒臨床療效及安全性。結(jié)果:治療前,兩組患兒發(fā)熱癥狀評(píng)分比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后,兩組患兒的發(fā)熱癥狀評(píng)分均降低(P0.05),其中治療組評(píng)分比對(duì)照組低(P0.05)。治療前,兩組患兒流涕癥狀評(píng)分比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后,兩組患兒的流涕癥狀評(píng)分均降低(P0.05),其中治療組評(píng)分比對(duì)照組低(P0.05)。治療前,兩組患兒咳嗽癥狀評(píng)分比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后,兩組患兒的咳嗽癥狀評(píng)分均降低(P0.05),其中治療組評(píng)分比對(duì)照組低(P0.05)。治療3 d后,對(duì)照組治愈11例(34.38%),好轉(zhuǎn)13例(40.63%),無(wú)效8例(25.00%),總有效率為75.00%;治療組治愈18(56.25%)例好轉(zhuǎn)14(42.42%)無(wú)效1(3.03%),總有效率為90.91%。治療組的治療有效率比對(duì)照組較高(P0.05)。在治療1 d時(shí),對(duì)照組TESS評(píng)分為1.23±0.17,治療組TESS評(píng)分為1.25±0.15,兩組之間無(wú)明顯差異(P0.05);治療3 d時(shí)對(duì)照組TESS評(píng)分為1.32±0.18,治療組TESS評(píng)分為1.34±0.19,兩組TESS評(píng)分無(wú)明顯差異(P0.05)。結(jié)論:熱毒寧聯(lián)合頭孢哌酮舒巴坦鈉對(duì)多重耐藥菌呼吸道感染患兒的治療有良好的臨床療效而且及安全性較好。
[Abstract]:Objective: to investigate the clinical efficacy and safety of Reduning combined with cefoperazone sulbactam sodium in the treatment of respiratory tract infection of multidrug resistant bacteria. Methods: 65 children with respiratory tract infection of multidrug resistant bacteria were randomly divided into two groups. 32 children in the control group were treated with cefoperazone sulbactam and 33 children in the treatment group were treated with Retinin injection for 3 days as a course of treatment. By comparing the changes of clinical symptoms, the total effective rate and the TESS score after treatment in the two groups, to explore the respiratory sensation of Redu Ning combined with cefoperazone sulbactam sodium to the multidrug resistant bacteria, the clinical symptoms of the two groups were compared before and after treatment, and the total effective rate and the TESS score after the treatment were compared. Clinical efficacy and safety of infected children. Results: before treatment, There was no significant difference in febrile symptom scores between the two groups (P 0.05). After treatment, the scores of fever symptoms in the two groups were all decreased (P 0.05), and the scores in the treatment group were lower than those in the control group (P 0.05). There was no significant difference in the score of snot symptoms between the two groups (P 0.05), but after treatment, the scores of the two groups were all decreased (P 0.05), and the scores of the treatment group were lower than those of the control group (P 0.05), and before treatment, the scores of the two groups were lower than those of the control group (P 0.05). There was no significant difference in cough symptom score between the two groups (P 0.05). After treatment, the cough symptom scores of the two groups were all decreased (P 0.05), and the score of the treatment group was lower than that of the control group (P 0.05). After 3 days of treatment, the score of the treatment group was lower than that of the control group. In the control group, 11 cases were cured, 13 cases were improved and 40.63%, 8 cases were ineffective, and the total effective rate was 75.00. The total effective rate was 75.00; in the treatment group, 1856.25 cases were cured and 1442.42) there was no effect. The total effective rate was 90.91.The effective rate of the treatment group was higher than that of the control group (P 0.05). At 1 day of treatment, the total effective rate of the treatment group was higher than that of the control group (P 0.05), and the total effective rate was 90.91.The total effective rate of the treatment group was higher than that of the control group. The TESS score of the control group was 1.23 鹵0.17, the TESS score of the treatment group was 1.25 鹵0.15, there was no significant difference between the two groups (P0.05), the TESS score of the control group was 1.32 鹵0.18 on the 3rd day of treatment, and the TESS score of the treatment group was 1.34 鹵0.19. There was no significant difference in TESS score between the two groups (P 0.05). Conclusion: Retinin combined with cefoperazone. Sulbactam sodium has good clinical efficacy and safety in the treatment of children with multidrug resistant bacteria respiratory tract infection.
【作者單位】： 南陽(yáng)市第一人民醫(yī)院;
【基金】：河南省創(chuàng)新型科技人才隊(duì)伍建設(shè)工程基金項(xiàng)目(2014GG032)
【分類號(hào)】：R725.6

【相似文獻(xiàn)】

中國(guó)期刊全文數(shù)據(jù)庫(kù) 前10條

1 岳博華;;多重耐藥菌管理聯(lián)席會(huì)在多重耐藥菌感染控制中的作用[J];中國(guó)當(dāng)代醫(yī)藥;2013年12期

2 薛海榮;;無(wú)縫隙管理模式在多重耐藥菌防控中的應(yīng)用[J];吉林醫(yī)學(xué);2014年13期

3 林榮;沈志君;;醫(yī)院多重耐藥菌目標(biāo)監(jiān)測(cè)報(bào)告[J];中國(guó)消毒學(xué)雜志;2011年04期

4 郭素青;;多重耐藥菌肺部感染231例回顧性分析[J];中外醫(yī)療;2011年33期

5 樊小開(kāi);陳曉嘉;;常見(jiàn)多重耐藥菌臨床分布特征及管理對(duì)策[J];世界中西醫(yī)結(jié)合雜志;2011年11期

6 曾慶洋;倪永圣;黃燕新;王陳龍;;醫(yī)院多重耐藥菌監(jiān)測(cè)的調(diào)查分析[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2011年21期

7 酈紅;;兒科多重耐藥菌醫(yī)院感染預(yù)防與控制[J];中國(guó)消毒學(xué)雜志;2012年03期

8 馬文暉;王力紅;張京利;趙霞;趙會(huì)杰;;信息化監(jiān)測(cè)在多重耐藥菌防控中的應(yīng)用[J];中國(guó)醫(yī)院管理;2012年03期

9 戴奕;;多重耐藥菌監(jiān)測(cè)分析與預(yù)防體會(huì)[J];天津護(hù)理;2012年02期

10 丁建芬;劉翠梅;何淳;胡凱;林海燕;;口腔醫(yī)院住院患者多重耐藥菌醫(yī)院感染監(jiān)測(cè)[J];臨床和實(shí)驗(yàn)醫(yī)學(xué)雜志;2012年09期

中國(guó)重要會(huì)議論文全文數(shù)據(jù)庫(kù) 前10條

1 章渭方;;多重耐藥菌:定植抑或致病[A];首屆西湖重癥醫(yī)學(xué)論壇暨2011年浙江省重癥醫(yī)學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2011年

2 付四毛;汪錫文;;探討目標(biāo)性監(jiān)控和管理兒科多重耐藥菌及醫(yī)院感染[A];中華醫(yī)學(xué)會(huì)第十七次全國(guó)兒科學(xué)術(shù)大會(huì)論文匯編（上冊(cè)）[C];2012年

3 詹傳華;;惡性腫瘤患者醫(yī)院感染多重耐藥菌的分析[A];中華醫(yī)學(xué)會(huì)第七次全國(guó)中青年檢驗(yàn)醫(yī)學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2012年

4 黃麗君;張麗霞;;18例肺結(jié)核合并多重耐藥菌肺部感染的護(hù)理[A];中華醫(yī)學(xué)會(huì)呼吸病學(xué)年會(huì)——2013第十四次全國(guó)呼吸病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2013年

5 賈輔忠;;院內(nèi)多重耐藥菌難治感染的監(jiān)控[A];中華醫(yī)院管理學(xué)會(huì)醫(yī)院感染管理專業(yè)委員會(huì)第九屆醫(yī)院感染管理學(xué)術(shù)年會(huì)論文匯編[C];2002年

6 劉運(yùn)喜;;如何利用計(jì)算機(jī)軟件監(jiān)控抗菌藥物和多重耐藥菌[A];中國(guó)醫(yī)院協(xié)會(huì)第十八屆全國(guó)醫(yī)院感染管理學(xué)術(shù)年會(huì)論文資料匯編[C];2011年

7 劉坤;袁曉寧;武迎宏;薛文英;;重癥監(jiān)護(hù)病房多重耐藥菌監(jiān)測(cè)與控制現(xiàn)狀分析[A];中國(guó)醫(yī)院協(xié)會(huì)第十八屆全國(guó)醫(yī)院感染管理學(xué)術(shù)年會(huì)論文資料匯編[C];2011年

8 湯麗霞;韋中盛;龍顯科;許桂丹;;多重耐藥菌醫(yī)院感染監(jiān)測(cè)及耐藥性分析[A];中國(guó)醫(yī)院協(xié)會(huì)第十八屆全國(guó)醫(yī)院感染管理學(xué)術(shù)年會(huì)論文資料匯編[C];2011年

9 梅衛(wèi)玲;傅政;楊永豐;;醫(yī)院感染管理信息系統(tǒng)在提升多重耐藥菌管理質(zhì)量中的作用[A];中國(guó)醫(yī)院協(xié)會(huì)第十八屆全國(guó)醫(yī)院感染管理學(xué)術(shù)年會(huì)論文資料匯編[C];2011年

10 李六億;賈會(huì)學(xué);賈建俠;趙秀莉;趙艷春;任軍紅;要慧;林金蘭;;某綜合醫(yī)院多重耐藥菌醫(yī)院感染控制效果的研究[A];中國(guó)醫(yī)院協(xié)會(huì)第十八屆全國(guó)醫(yī)院感染管理學(xué)術(shù)年會(huì)論文資料匯編[C];2011年

中國(guó)重要報(bào)紙全文數(shù)據(jù)庫(kù) 前8條

1 記者 孫夢(mèng);多重耐藥菌院感防控有了技術(shù)指南[N];健康報(bào);2011年

2 河北聯(lián)合大學(xué)附屬醫(yī)院 王玉芳;護(hù)士勿忘多重耐藥菌防控職責(zé)[N];健康報(bào);2012年

3 中南大學(xué)湘雅醫(yī)院感染控制中心主任 吳安華;應(yīng)對(duì)多重耐藥菌分兩步走[N];健康報(bào);2014年

4 衛(wèi)新辦;醫(yī)院要從多學(xué)科角度加強(qiáng)監(jiān)控[N];保健時(shí)報(bào);2008年

5 樊丹邋柴玉;衛(wèi)生部要求加強(qiáng)多重耐藥菌醫(yī)院感染控制工作[N];中國(guó)中醫(yī)藥報(bào);2008年

6 記者 陳青;術(shù)后用抗生素別超48小時(shí)[N];文匯報(bào);2011年

7 本報(bào)記者 王霞;打造醫(yī)院感控執(zhí)行力[N];醫(yī)藥經(jīng)濟(jì)報(bào);2012年

8 記者 羅爭(zhēng)光　仇逸;和細(xì)菌耐藥“賽跑”,我們能領(lǐng)先嗎?[N];新華每日電訊;2010年

中國(guó)博士學(xué)位論文全文數(shù)據(jù)庫(kù) 前1條

1 趙薇;SICU多重耐藥菌定植感染監(jiān)測(cè)及傳播動(dòng)力學(xué)研究[D];吉林大學(xué);2009年

中國(guó)碩士學(xué)位論文全文數(shù)據(jù)庫(kù) 前5條

1 李嬌;綜合ICU多重耐藥菌院內(nèi)傳播的預(yù)警模式構(gòu)建及分析[D];山西醫(yī)科大學(xué);2016年

2 胡素佩;集束化干預(yù)措施防控ICU多重耐藥菌醫(yī)院感染的效果評(píng)價(jià)[D];浙江大學(xué);2016年

3 劉士波;骨折術(shù)后感染多重耐藥菌調(diào)查與分析[D];河北醫(yī)科大學(xué);2011年

4 崔南;hBD1穩(wěn)定表達(dá)細(xì)胞株的建立及其表達(dá)產(chǎn)物對(duì)多重耐藥菌的活性檢測(cè)[D];蘭州大學(xué);2012年

5 陳雪梅;重癥監(jiān)護(hù)病房醫(yī)院感染病原菌監(jiān)測(cè)、耐藥性分析及預(yù)防[D];廣州醫(yī)學(xué)院;2011年

，

本文編號(hào)：1662079